81. Nucleosides for the treatment of respiratory RNA virus infections. Issue 1 (March 2018) Authors: Jordan, Paul C; Stevens, Sarah K; Deval, Jerome Journal: Antiviral chemistry & chemotherapy Issue: Volume 26:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
82. Past and Future. Current Drugs Targeting HIV-1 Integrase and Reverse Transcriptase-Associated Ribonuclease H Activity: Single and Dual Active Site Inhibitors. Issue 4 (August 2014) Authors: Esposito, Francesca; Tramontano, Enzo Journal: Antiviral chemistry & chemotherapy Issue: Volume 23:Issue 4(2014) Page Start: 129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
83. Past and Future. Current Drugs Targeting HIV-1 Integrase and Reverse Transcriptase-Associated Ribonuclease H Activity: Single and Dual Active Site Inhibitors. Issue 4 (August 2014) Authors: Esposito, Francesca; Tramontano, Enzo Journal: Antiviral chemistry & chemotherapy Issue: Volume 23:Issue 4(2014) Page Start: 129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
84. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Issue 1 (May 2018) Authors: Slusarczyk, Magdalena; Serpi, Michaela; Pertusati, Fabrizio Journal: Antiviral chemistry & chemotherapy Issue: Volume 26:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
85. Polarized macrophage subsets differentially express the drug efflux transporters MRP1 and BCRP, resulting in altered HIV production. Issue 1 (January 2018) Authors: He, Hui; Buckley, Merrion; Britton, Bernard; Mu, Ying; Warner, Kristin; Kumar, Santosh; Cory, Theodore J Journal: Antiviral chemistry & chemotherapy Issue: Volume 26:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
86. Potential of small-molecule fungal metabolites in antiviral chemotherapy. Issue 2 (August 2017) Authors: Roy, Biswajit G Journal: Antiviral chemistry & chemotherapy Issue: Volume 25:Issue 2(2017) Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
87. Predicting Zika virus structural biology: Challenges and opportunities for intervention. Issue 3 (August 2015) Authors: Cox, Bryan D; Stanton, Richard A; Schinazi, Raymond F Journal: Antiviral chemistry & chemotherapy Issue: Volume 24:Issue 3/4(2015) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
88. Prodrugs of herpes simplex thymidine kinase inhibitors. Issue 2 (April 2015) Authors: Yanachkova, Milka; Xu, Wei-Chu; Dvoskin, Sofya; Dix, Edward J; Yanachkov, Ivan B; Focher, Federico; Savi, Lida; Sanchez, M Dulfary; Foster, Timothy P; Wright, George E Journal: Antiviral chemistry & chemotherapy Issue: Volume 24:Issue 2(2015) Page Start: 47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
89. Professor De Clercq and 25 Years of International Collaboration on Antiviral Research. Issue 2 (April 2013) Authors: Colacino, Joseph M Journal: Antiviral chemistry & chemotherapy Issue: Volume 23:Issue 2(2014) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
90. Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment. (November 2020) Authors: Lee, Sun Hee; Shin, Hyun Phil; Lee, Joung Il Journal: Antiviral chemistry & chemotherapy Issue: Volume 28(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗